ImmunoSarc: Sunitinib and/​or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Treatment of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Agents: Sunitinib Phase III Status Recruiting Sponsor Abbisko Therapeutics Co, Ltd For further information please also consult ClinicalTrials.gov.   This is a Phase III Study of ABSK021 to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor WHO…

Read More

SPAGN publications

Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts Silvia Stacchiotti, Hans-Roland Duerr, Sydney Stern, Michiel van der Sande, Sebastian Bauer et al. Cancer Treatment Reviews 112, 102491, January 2023 Open Access here The role of patient advocates and sarcoma community initiatives in musculoskeletal oncology. Moving towards Evidence-Based…

Read More

Sarcoma Centers

Specialized centers with multi-disciplinary teams: A must in sarcomas! What is a sarcoma centre? Sarcomas are rare. It is therefore very important to find physicians who have experience with this disease. Please read our thoughts on what sarcoma specialist centres should comprise here. Find more information about the importance of sarcoma centres here or watch…

Read More

Guidelines

Medical societies such as the European Society of Medical Oncology (ESMO) in Europe or the National Comprehensive Cancer Network (NCCN) create guidelines which outline the standards of care for different types of cancer – among them guidelines for soft tissue sarcoma, bone sarcoma and GIST. These guidelines provide recommendations about diagnosis, treatment and follow-up for…

Read More